[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353019-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353019-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","delta-like-ligand-3directed-225ac-radioimmunotherapy-in-neuroendocrine-lung-and-prostate-cancer-models","Delta-like Ligand 3–Directed 225Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models","","Delta-like ligand 3 (DLL3) is a tumor-selective Notch inhibitory ligand and an actionable target in neuroendocrine cancers. The study evaluated in vivo performance of the anti-DLL3 monoclonal antibody TDI-Y-010, covalently linked to a MACROPA-derived chelator (mcp), for 225Ac radioimmunotherapy. Ex vivo biodistribution and dosimetry informed therapeutic dosing in DLL3-positive lung (Lu149) and prostate (H660) xenograft models. Median survival increased significantly versus saline and versus an Fc-matched control, while hematologic toxicity remained transient and comparable across groups. Background organ histopathology showed only mild-to-moderate kidney and ovary toxicity in selected cohorts, supporting clinical potential.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/delta-like-ligand-3directed-225ac-radioimmunotherapy-in-neuroendocrine-lung-and-prostate-cancer-models/353019/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/delta-like-ligand-3directed-225ac-radioimmunotherapy-in-neuroendocrine-lung-and-prostate-cancer-models/353019.png","ImageObject",300,407,{"name":42,"@type":43},"McQueen","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What therapeutic agent was evaluated for 225Ac radioimmunotherapy?","Question",{"text":63,"@type":64},"An anti-DLL3 monoclonal antibody, TDI-Y-010, covalently linked to a MACROPA-derived chelator (mcp) to form [225Ac]Ac-mcp-TDI-Y-010 for in vivo testing.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were dosing levels selected for the mouse efficacy studies?",{"text":68,"@type":64},"Ex vivo biodistribution and dosimetry data were used to determine appropriate therapeutic dosing before testing multiple [225Ac]Ac-mcp-TDI-Y-010 dose levels in xenograft models.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key efficacy and safety findings?",{"text":72,"@type":64},"Treatment significantly extended median survival versus saline and versus [225Ac]Ac-mcp-IgG4 in the respective models, while hematologic toxicity was transient and comparable across cohorts. Histopathology indicated mild-to-moderate kidney and ovary toxicity in selected groups.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353019,1790784588,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Delta-like Ligand 3–Directed 225Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models  \nTran T. Hoang 1,2, David Bauer†2, Aidan Ingham2, Ileana C. Miranda3, Lukas M. Carter4, Alexa Michel2, Roberto De Gregorio2, Juliana Welk 1,2, Hong Zhong5, John T. Poirier6, Michael J. Morris5, Lisa Bodei7, Charles M. Rudin* 1,5, Salomon Tendler*2,5, and Jason S. Lewis* 1,2,7  \n1Department of Pharmacology, Weill Cornell Graduate School of Medical Sciences, New York, New York; 2Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York; 3Laboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, and The Rockefeller University, New York, New York; 4Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York; 5Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; 6Perlmutter Cancer Center, New York University Langone Health, New York, New York; and 7Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York  \nThis work evaluated the in vivo performance of an anti–delta-like ligand 3 (DLL3) monoclonal antibody, TDI-Y-010, covalently linked to the MACROPA-derived chelator (mcp) for 225Ac radioimmunotherapy in 2 DLL3-positive neuroendocrine cancer models of the lung and prostate. Methods: Ex vivo biodistribution studies were conducted to evaluate the uptake of [225Ac]Ac-mcp-TDI-Y-010 and determine appropriate therapeutic dosing. On the basis of dosimetry data, 3 doses of [225Ac]Ac-mcp-TDI-Y-010 (9 .25, 18 .5, and 37 .0 kBq) were evaluated in female nude mice bearing Lu149 small cell lung cancer patient-derived xenografts. An additional therapeutic efﬁcacy study was conducted in male nude mice bearing H660 neuroendocrine prostate cancer xenografts, with administered doses of 4.63, 9.25, and 18.5 kBq. Results: In the Lu149 model, the median survival of the [225Ac]Ac-mcp-TDI-Y-010 treatment groups was signiﬁcantly longer than that of the saline treatment cohorts (P , 0.0001 and P 5 0.0002, respectively) . In the neuroendocrine prostate cancer model, median survival was signiﬁcantly longer for mice in the [225Ac]Ac-mcp-TDI-Y- 010 groups than in those treated with [225Ac]Ac-mcp-IgG4 (median survival, 37 d; P 5 0.002, 0 .0001, and 0 .0006 for the 4 .63-, 9 .25-, and 18.5-kBq [225Ac]Ac-mcp-TDI-Y-010 groups, respectively) . Hematologic toxicity was transient in both models and comparable across all cohorts. Histopathologic assessment of background organs demonstrated mild to moderate kidney and ovary toxicity in the SC16 group compared with the highest-dose TDI-Y-010 cohort (37.0 kBq) . Conclusion: [225Ac]Ac-mcp-TDI-Y-010 exhibited excellent antitumor efﬁcacy with mild and transient hematologic toxicity, supporting its potential as a radioimmunotherapeutic agent for patients with DLL3-expressing neuroendocrine cancers.  \nKeyWords: neuroendocrine cancer; radionuclide therapy; 225Ac; DLL3; radioimmunotherapy  \nJ Nucl Med 2026; 67:943–949  \nDOI: 10.2967/jnumed.125.271302  \nReceived Sep. 24, 2025; revision accepted Feb. 17, 2026 .  \nFor correspondence, contact Jason Lewis ([lewisj2@mskcc.org](lewisj2@mskcc.org)).  \n*Contributed equally to this work.  \n†Current address: Molecular Imaging and Theranostics Center, University of Missouri, Columbia, Missouri.  \nPublished online Mar. 26, 2026 .  \nImmediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: [https://creativecommons](https://creativecommons). org/licenses/by/4.0/. Details: [https://jnm.snmjournals.org/page/permissions](https://jnm.snmjournals.org/page/permissions).  \nCOPYRIGHT 􀀁 2026 by the Society of Nuclear Medicine and Molecular Imaging.  \nDelta-like ligand 3 (DLL3) is a Notch inhibitory ligand  \nnormally expressed at low levels in healthy adult neuronal tissues but overexpressed on t","cbCaiu43Nu236Znx","https://ap.wps.com/l/cbCaiu43Nu236Znx","pdf",1563978,"English","# Background and target rationale\n## DLL3 expression in neuroendocrine tumors\n# Antibody-radiolabel strategy\n## TDI-Y-010-mcp construct\n## Comparison with prior SC16 approach\n# Study design and methods\n## Ex vivo biodistribution and dosimetry\n## Therapeutic efficacy models and dosing\n# Results\n## Survival outcomes in lung model\n## Survival outcomes in prostate model\n## Toxicity and histopathology\n# Conclusion and implications","[{\"question\":\"What therapeutic agent was evaluated for 225Ac radioimmunotherapy?\",\"answer\":\"An anti-DLL3 monoclonal antibody, TDI-Y-010, covalently linked to a MACROPA-derived chelator (mcp) to form [225Ac]Ac-mcp-TDI-Y-010 for in vivo testing.\"},{\"question\":\"How were dosing levels selected for the mouse efficacy studies?\",\"answer\":\"Ex vivo biodistribution and dosimetry data were used to determine appropriate therapeutic dosing before testing multiple [225Ac]Ac-mcp-TDI-Y-010 dose levels in xenograft models.\"},{\"question\":\"What were the key efficacy and safety findings?\",\"answer\":\"Treatment significantly extended median survival versus saline and versus [225Ac]Ac-mcp-IgG4 in the respective models, while hematologic toxicity was transient and comparable across cohorts. Histopathology indicated mild-to-moderate kidney and ovary toxicity in selected groups.\"}]","Delta-like Ligand 3–Directed 225Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models | PDF",1790102591,18,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/54e36da309e93b28d1c9f8503002ed72.webp",983,1296,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ba96e9c5bdd4de2e57f9709ca7ed361.webp",982,1294,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/17af8e4623b02d728fa316f663a21ac1.webp",981,1293,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e1eba7c3dacd6cf03d4ab3edbf933181.webp",980,1292]